Get started
CRISPR THERAPEUTICS AG COM CHF0.03CRISPR THERAPEUTICS AG COM CHF0.03CRISPR THERAPEUTICS AG COM CHF0.03

CRISPR THERAPEUTICS AG COM CHF0.03

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0VRQ chart


Full chart

0VRQ upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.48 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.5 USD
Net income (FY)
‪−366.25 M‬ USD
Revenue (FY)
‪37.31 M‬ USD
Shares float
‪82.09 M‬
Beta (1Y)
1.94

Employees


Employees (FY)
393
Change (1Y)
−14 −3.44%
Revenue / Employee (1Y)
‪94.95 K‬ USD
Net income / Employee (1Y)
‪−931.94 K‬ USD

About CRISPR Therapeutics AG


Sector
Health Technology
Industry
Biotechnology
CEO
Samarth Kulkarni
Website
crisprtx.com
Headquarters
Zug
Founded
2013
ISIN
CH0334081137
FIGI
BBG00JSC0TQ9
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0VRQ news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0VRQ is 53.5 USD — it has increased by 3.55% in the past 24 hours. Watch CRISPR THERAPEUTICS AG COM CHF0.03 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange CRISPR THERAPEUTICS AG COM CHF0.03 stocks are traded under the ticker 0VRQ.
0VRQ stock has risen by 31.69% compared to the previous week, the month change is a 32.17% rise, over the last year CRISPR THERAPEUTICS AG COM CHF0.03 has showed a −35.20% decrease.
We've gathered analysts' opinions on CRISPR THERAPEUTICS AG COM CHF0.03 future price: according to them, 0VRQ price has a max estimate of 268.00 USD and a min estimate of 32.00 USD. Watch 0VRQ chart and read a more detailed CRISPR THERAPEUTICS AG COM CHF0.03 stock forecast: see what analysts think of CRISPR THERAPEUTICS AG COM CHF0.03 and suggest that you do with its stocks.
0VRQ reached its all-time high on Jan 15, 2021 with the price of 216.5 USD, and its all-time low was 14.0 USD and was reached on Dec 16, 2021. View more price dynamics on 0VRQ chart.
See other stocks reaching their highest and lowest prices.
0VRQ stock is 7.17% volatile and has beta coefficient of 1.94. Track CRISPR THERAPEUTICS AG COM CHF0.03 stock price on the chart and check out the list of the most volatile stocks — is CRISPR THERAPEUTICS AG COM CHF0.03 there?
Today CRISPR THERAPEUTICS AG COM CHF0.03 has the market capitalization of ‪4.48 B‬, it has decreased by −6.16% over the last week.
Yes, you can track CRISPR THERAPEUTICS AG COM CHF0.03 financials in yearly and quarterly reports right on TradingView.
CRISPR THERAPEUTICS AG COM CHF0.03 is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
0VRQ earnings for the last quarter are −0.44 USD per share, whereas the estimation was −1.20 USD resulting in a 63.35% surprise. The estimated earnings for the next quarter are −1.24 USD per share. See more details about CRISPR THERAPEUTICS AG COM CHF0.03 earnings.
CRISPR THERAPEUTICS AG COM CHF0.03 revenue for the last quarter amounts to ‪35.69 M‬ USD, despite the estimated figure of ‪8.06 M‬ USD. In the next quarter, revenue is expected to reach ‪6.84 M‬ USD.
0VRQ net income for the last quarter is ‪−37.31 M‬ USD, while the quarter before that showed ‪−85.94 M‬ USD of net income which accounts for 56.59% change. Track more CRISPR THERAPEUTICS AG COM CHF0.03 financial stats to get the full picture.
No, 0VRQ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 19, 2025, the company has 393.00 employees. See our rating of the largest employees — is CRISPR THERAPEUTICS AG COM CHF0.03 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CRISPR THERAPEUTICS AG COM CHF0.03 EBITDA is ‪−447.25 M‬ USD, and current EBITDA margin is ‪−1.20 K‬%. See more stats in CRISPR THERAPEUTICS AG COM CHF0.03 financial statements.
Like other stocks, 0VRQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CRISPR THERAPEUTICS AG COM CHF0.03 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CRISPR THERAPEUTICS AG COM CHF0.03 technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CRISPR THERAPEUTICS AG COM CHF0.03 stock shows the neutral signal. See more of CRISPR THERAPEUTICS AG COM CHF0.03 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.